for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Innovent Biologics Says Revenue Attributable To Sales Of Tyvyt (Sintilimab Injection) In Q1 Around Rmb400 Million

April 23 (Reuters) - Innovent Biologics Inc:

* REVENUE ATTRIBUTABLE TO SALES OF TYVYT (SINTILIMAB INJECTION) IN Q1 AROUND RMB400 MILLION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up